Blocking Telomere Damage Signals Restores Blood Stem Cell Function in Aging

Aging blood stem cells are a silent driver of immune decline, anemia, and increased disease risk in older adults. As telomeres shorten over a lifetime, they accumulate damage that triggers a specialized cellular alarm system — the telomeric DNA damage response (tDDR). Until now, whether this alarm system directly caused hematopoietic decline or was merely a bystander was unclear.

Researchers at IFOM and collaborating Italian institutions investigated this question using telomerase-deficient Terc-/- mice, which rapidly develop telomere shortening and hematopoietic dysfunction that mirrors human aging. The team targeted the tDDR using telomeric antisense oligonucleotides (tASOs) — short synthetic RNA molecules designed to block the noncoding RNA signals that activate the damage response at telomere ends.

In Terc-/- mice, tASO treatment suppressed tDDR activity in blood-forming organs, reduced markers of senescence and chronic inflammation, and meaningfully improved blood cell output. Hematopoietic stem cells showed restored fitness and enhanced ability to repopulate the blood system in transplant experiments — a gold-standard measure of stem cell function. Comparable benefits were observed in aged wild-type mice with naturally shortened telomeres.

The most translationally significant finding came from human data: ex vivo tASO treatment of hematopoietic stem cells obtained from elderly human donors improved their functional performance, demonstrating cross-species relevance and therapeutic potential.

These results establish the tDDR not just as a marker but as an active, causal driver of hematopoietic aging — and tASO therapy as a mechanistically precise way to interrupt that process. The lead researcher holds patents and equity in a company (TAG Therapeutics) developing this approach, which warrants acknowledgment. The study is based on the abstract only, and full methodology and safety data require access to the complete paper.